Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Sjögren's Syndrome
NCT05124925Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Primary endpoint: Change in logarithm of salivary gland B/B+T cell ratio at 25 weeks. Started Jul 2022; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT05124925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124925.